Search research articles
Contact Us
Filters
Showing results (181-190 of 199) with videos related to
Page
of 20
Sort By:
Cancer Research
|
January 18, 2011
CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors
Victoria E Anderson, Michael I Walton, Paul D Eve, et al.
Chemical Communications (Cambridge, England)
|
September 13, 2012
Tuning the breathing behaviour of MIL-53 by cation mixing
Farid Nouar, Thomas Devic, Hubert Chevreau, et al.
Dalton Transactions (Cambridge, England : 2003)
|
December 6, 2021
Investigation of the preparation and reactivity of metal-organic frameworks of cerium and pyridine-2,4,6-tricarboxylate
Juliana Fonseca de Lima, Fernanda V S Moreno, Bruno A T Menezes, et al.
Molecular Cancer Therapeutics
|
January 8, 2010
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106
Michael I Walton, Paul D Eve, Angela Hayes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2005
In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202
Florence I Raynaud, Steven R Whittaker, Peter M Fischer, et al.
Journal of Medicinal Chemistry
|
July 4, 2009
Identification of inhibitors of checkpoint kinase 1 through template screening
Thomas P Matthews, Suki Klair, Samantha Burns, et al.
Inorganic Chemistry
|
December 23, 2017
23-Electron Octahedral Molybdenum Cluster Complex [{Mo<sub>6</sub>I<sub>8</sub>}Cl<sub>6</sub>]<sup></sup>
Natalya A Vorotnikova, Yuri A Vorotnikov, Igor N Novozhilov, et al.
Genome Biology
|
September 17, 2016
DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer
Nnennaya Kanu, Maria Antonietta Cerone, Gerald Goh, et al.
Molecular Cancer Therapeutics
|
April 29, 2010
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth
Kyla M Grimshaw, Lisa-Jane K Hunter, Timothy A Yap, et al.
Journal of Medicinal Chemistry
|
October 23, 2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors
Michael Lainchbury, Thomas P Matthews, Tatiana McHardy, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 199) with videos related to
Sort By:
Page
of 20
Cancer Research
|
January 18, 2011
CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors
Victoria E Anderson, Michael I Walton, Paul D Eve, et al.
Chemical Communications (Cambridge, England)
|
September 13, 2012
Tuning the breathing behaviour of MIL-53 by cation mixing
Farid Nouar, Thomas Devic, Hubert Chevreau, et al.
Dalton Transactions (Cambridge, England : 2003)
|
December 6, 2021
Investigation of the preparation and reactivity of metal-organic frameworks of cerium and pyridine-2,4,6-tricarboxylate
Juliana Fonseca de Lima, Fernanda V S Moreno, Bruno A T Menezes, et al.
Molecular Cancer Therapeutics
|
January 8, 2010
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106
Michael I Walton, Paul D Eve, Angela Hayes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2005
In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202
Florence I Raynaud, Steven R Whittaker, Peter M Fischer, et al.
Journal of Medicinal Chemistry
|
July 4, 2009
Identification of inhibitors of checkpoint kinase 1 through template screening
Thomas P Matthews, Suki Klair, Samantha Burns, et al.
Inorganic Chemistry
|
December 23, 2017
23-Electron Octahedral Molybdenum Cluster Complex [{Mo<sub>6</sub>I<sub>8</sub>}Cl<sub>6</sub>]<sup></sup>
Natalya A Vorotnikova, Yuri A Vorotnikov, Igor N Novozhilov, et al.
Genome Biology
|
September 17, 2016
DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer
Nnennaya Kanu, Maria Antonietta Cerone, Gerald Goh, et al.
Molecular Cancer Therapeutics
|
April 29, 2010
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth
Kyla M Grimshaw, Lisa-Jane K Hunter, Timothy A Yap, et al.
Journal of Medicinal Chemistry
|
October 23, 2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors
Michael Lainchbury, Thomas P Matthews, Tatiana McHardy, et al.
Page
of 20